Introduction Introduction
Hepatitis E virus (HEV) is an emerging infectious threat to blood safety. [1] We report a unique case wherein the donor initiated a callback and helped us to diagnose HEV and curb the viral transmission. There are documented cases from Japan, the United Kingdom, Saudi Arabia and France on the transmissibility of HEV via blood transfusions in patients. [2] [3] [4] [5] HEV is a nonenveloped, single-stranded RNA virus, 27-34 nm in diameter. The virus may be transmitted enterically, via blood transfusions or a zoonotic spread by consumption of uncooked meat. Four genotypes of HEV have been identifi ed. Genotypes 1 and 2 are human viruses causing epidemic hepatitis and are associated with waterborne and fecal -oral transmission. Genotypes 3 and 4 are swine viruses that are common in domestic and wild pigs. The extent of transmission and its clinical relevance are issues under debate. At present, there is little evidence to advocate universal screening for this virus. However, considering that there is no defi nitive treatment for HEV-induced hepatitis, selective screening should be advocated in blood products for high-risk recipients in endemic areas. [1] Case Report Case Report
An apparently healthy, 27-year-old Indian male donor passed all eligibility criteria tests and donated blood (triple bag) at a tertiary cancer hospital. After 20 days, the donor informed the blood bank that he had developed vomiting and jaundice 1 day postdonation, for which he had visited a physician and was investigated in a local laboratory, wherein the liver function tests were found to be elevated [ Table 1 ].
The donor contacted our blood bank 20 days after donation and conveyed about an outbreak of similar symptoms in his residential community during the same period. Accordingly, we investigated him for hepatitis A and E virus in the microbiology laboratory of our hospital. Hepatitis E IgM antibody by enzyme-linked immunosorbent assay (ELISA) was found to be positive. The hepatitis A IgM antibody by chemiluminiscent microparticle immunoassay was negative. There was improvement in the liver profi le as compared to prior reports [ Table 2 ].
The donor's packed cells had already been issued during this interim period of 20 days as all mandatory TTI tests had been negative. The patient receiving the implicated packed cells was symptom free 35 days posttransfusion. Laboratory investigations could not be performed as he had already been discharged and was a resident of another state. The cryoprecipitate unit and factor VIII-defi cient plasma were discarded immediately to prevent the possibility of HEV transmission.
Discussion Discussion
There are widespread endemic zones of hepatitis E [ Figure 1 ]. HEV seroprevalence in blood donors reported from various countries ranges from 1% to 52% [ Table 3 ].
The disease manifests as malaise, fever, gastrointestinal symptoms and jaundice, and is 
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usually self-limiting, resolving within 4-6 weeks. A fulminant hepatitis may develop in susceptible patients like pregnant females, preexisting liver disease and immunocompromised patients with fatal outcomes. Our donor was in the incubation phase during blood donation, but his initiated call back was pivotal in detecting HEV IgM antibodies. The incubation period ranges from 3 to 8 weeks. The subclinical nature of HEV disease has huge implications for blood banks, as a donor may give a negative history for jaundice even though he may be anti-HEV antibody positive. Anti-HEV IgM antibody indicates acute infection [ Figure 2 ]. Anti-HEV IgG titer may remain detectable for up to 15 years. [8] The currently available anti-HEV antibody (IgG and IgM) assays are not FDA approved, with wide variations in their sensitivity and specifi city. Reliable assays for IgG and IgM anti-HEV antibodies and molecular tests for HEV RNA are critically needed. [9] A pedigreed panel of HEV sera from infected patients globally needs to be established to validate assays. Unexplained acute or chronic hepatitis warrants an IgM anti-HEV test to rule out ongoing infection. Molecular tests based on HEV RNA detection in serum and stool may be utilized for confi rmation, genotyping and epidemiological studies. Because of the limitations of this technique, IgM ELISA test for detection of clinical and subclinical acute infection would be cost-effective in a blood bank setting.
Hepatitis E is being considered as a re-emerging infectious disease across the world. Routine screening for the virus is presently not performed in blood banks; however, studies performed globally indicate a high HEV seroprevalence (1-52%) in blood donors. Being a referral cancer center, our donor population is a mix of individuals from various Indian states, and may help in understanding the HEV seroprevalance of blood donors in India as there is a dearth of literature on the same. Pilot projects to test donors for HEV would help in gauging the actual seroprevalance and facilitate in hepatitis E screening policy decisions for specifi c geographical locations. Screening donor blood for HEV may be worthwhile in hyperendemic regions. Because of the absence of defi nitive treatment and vaccination, HEV is presently creating many challenges to the blood bank community. 
